First, our results showed that there was a significant difference in the expression of SCHIP1 between the tumor and normal, and the SCHIP1 also had a poor prognosis in TCGA-AML cohort (Figures 7A, B). This evidence concerns the gene SCHIP1 and acute myeloid leukemia.